Madhavan obtained his PhD at Jacobs University Bremen, Germany before doing postdoctoral work at the Radboud University Nijmegen, The Netherlands, and finally moved to Singapore. He spent more than 15 years developing the polymersome technology, while at Institute of Materials Research and Engineering (IMRE, A*STAR) and as an Asst. Professor at Nanyang Technological University (NTU) Singapore. He has translated the science of polymersomes to a technology platform and founded ACM Biolabs Pte Ltd, in Singapore, in 2013. Since its inception, he developed the company’s overall product strategy and product portfolio. He founded ACM’s subsidiary AAVACC Pte Ltd in 2017, establishing its veterinary vaccines and licensed out to San group. In 2020, ACM Biolabs set-up its subsidiary ACM Biosciences AG in Basel, Switzerland. Currently, ACM lead product, 2nd Gen COVID vaccine has completed successful Phase 1 clinical studies and a pipeline of therapeutics are being developed.